Avalon Trust’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$153K Buy
774
+599
+342% +$115K 0.01% 174
2025
Q4
$32.2K Hold
175
﹤0.01% 322
2025
Q3
$26.9K Hold
175
﹤0.01% 374
2025
Q2
$24.5K Sell
175
-268
-60% -$37.6K ﹤0.01% 312
2025
Q1
$65.1K Buy
443
+268
+153% +$38.8K 0.01% 219
2024
Q4
$22.9K Sell
175
-600
-77% -$84K ﹤0.01% 286
2024
Q3
$121K Sell
775
-600
-44% -$96.9K 0.01% 152
2024
Q2
$214K Hold
1,375
0.02% 124
2024
Q1
$186K Sell
1,375
-400
-23% -$53K 0.02% 137
2023
Q4
$239K Sell
1,775
-88
-5% -$11.4K 0.02% 114
2023
Q3
$252K Hold
1,863
0.03% 104
2023
Q2
$267K Hold
1,863
0.02% 112
2023
Q1
$259K Buy
+1,863
New +$251K 0.03% 109

Other funds holding AZN

Avalon Trust's AZN Position: Q1 2026 in Review

Avalon Trust increased its AstraZeneca (AZN) stake by 342% in Q1 2026, buying an estimated $115K and bringing the position to 774 shares worth $153K. The position accounts for 0.01% of the portfolio, ranked #174.

Avalon Trust first reported a position in AZN in Q1 2023 and has held it in 13 quarters since. The position peaked at $267K in Q2 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Avalon Trust held 774 shares of AstraZeneca worth $153K as of Q1 2026.
  • Avalon Trust bought 599 AstraZeneca shares in Q1 2026, an estimated $115K.
  • AstraZeneca made up 0.01% of Avalon Trust's portfolio in Q1 2026, its #174 holding.
  • Avalon Trust first reported a position in AstraZeneca in Q1 2023 and has held it in 13 quarters since.
  • Avalon Trust's AstraZeneca position peaked at $267K in Q2 2023.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Avalon Trust's 13F filing for Q1 2026, filed 6 May 2026.